Show simple item record

dc.contributor.authorAbreu, D. R.
dc.contributor.authorReck, M.
dc.contributor.authorSendur, N.
dc.contributor.authorPark, K.
dc.contributor.authorLee, D. H.
dc.contributor.authorCicin, I.
dc.contributor.authorYumuk, P. F.
dc.contributor.authorOrlandi, F. J.
dc.contributor.authorLeal, T. A.
dc.contributor.authorSoparattanapaisarn, N.
dc.contributor.authorLangleben, A.
dc.contributor.authorCalifano, Raffaele
dc.contributor.authorMedgyasszay, B.
dc.contributor.authorHsia, T. C.
dc.contributor.authorOtterson, G. A.
dc.contributor.authorWoods, T.
dc.contributor.authorJensen, E.
dc.contributor.authorSamkari, A.
dc.contributor.authorBoyer, M.
dc.date.accessioned2022-04-28T13:57:38Z
dc.date.available2022-04-28T13:57:38Z
dc.date.issued2022en
dc.identifier.citationAbreu DR, Reck M, Sendur N, Park K, Lee DH, Cicin I, et al. Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score >= 50%: KEYNOTE-598 3-year follow-up. Annals of Oncology. 2022;33:S30-S1.en
dc.identifier.doi10.1016/j.annonc.2022.02.015en
dc.identifier.urihttp://hdl.handle.net/10541/625144
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.annonc.2022.02.015en
dc.titlePembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score >= 50%: KEYNOTE-598 3-year follow-upen
dc.typeMeetings and Proceedingsen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2022-06-28T09:43:18Z


Files in this item

Thumbnail
Name:
Abreu.pdf
Size:
141.0Kb
Format:
PDF
Description:
Identified with Open Access button

This item appears in the following Collection(s)

Show simple item record